Global Ankylosing Spondylitis (AS) Market growing by Increasing Market Share and Forecast 2026 with
Global Ankylosing Spondylitis (AS) Market By Drug Type (Nonsteroidal Anti-Inflammatory Drugs, TNF Blockers, Immunosuppressive Drugs, Anti-Inflammatory Drugs, Steroids, JAK Inhibitors, Others), Application (Juveniles, Adults), Molecule (Biologics, Biosimilars, Small Molecules), Route of Administration (Parenteral, Oral)
Market Analysis: Global Ankylosing Spondylitis (AS) MarketGlobal ankylosing spondylitis (AS) market is set to witness a substantial CAGR in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. Increasing cases of ankylosing spondylitis worldwide and increasing healthcare expenditure is the factor for the growth of this market.
Get Exclusive Sample Report: @
Market Definition: Global Ankylosing Spondylitis (AS) MarketAnkylosing spondylitis or AS is a kind of an arthritis which usually affect the spine of the patient by reducing the flexibility. This usually causes discomfort, pain, stiffness and inflammation. In some cases, spines get fused in fixed position due to new bone formation. Usually drugs such as nonsteroidal anti- inflammatory, TNF blockers, steroids, JAK inhibitors and others are used to treat this disease. This disease mainly creates stiffness in areas such as small joints, ribs, heels, hips and others. According to National Health and Nutritional Examination Survey (NHANES), in the U.S., 0.5 percent of the population or about 1.6 million people are affected by ankylosing spondylitis.
Market Drivers
- Increasing cases of ankylosing spondylitis worldwide is the factor for the growth of this market
- Rising research and development expenditure will also propel the growth of the market
- Increasing number of population looking for solution for ankylosing spondylitis will also drive market growth
- Development in healthcare industry will also drive market growth
Market Restraints
- Loss of patent exclusivity is the factor restraining the market growth
- Issues associated with the copyright will also act as a factor restraining the market growth
Segmentation: Global Ankylosing Spondylitis (AS) Market
By Drug Type
- Nonsteroidal Anti-Inflammatory Drugs
- TNF Blockers
- Immunosuppressive Drugs
- Anti-Inflammatory Drugs
- Steroids
- JAK Inhibitors
- Others
By Application
- Juveniles
- Adults
By Molecule
- Biologics
- Biosimilars
- Small Molecules
By Route of Administration
- Parenteral
- Oral
Key Developments in the Market:
- In December 2017, Izana Bioscience announced the launch of their new clinical-stage translational medicine company which will mainly concentrate on the development of namilumab in ankylosing spondylitis. The company also signed an agreement with Takeda Pharmaceutical Company Limited for the rights of manufacturing and commercialization of the product. The main aim of the launch is to provide better treatment and solutions to the people who are suffering from ankylosing spondylitis
Competitive Analysis:
Global ankylosing spondylitis (AS) market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of ankylosing spondylitis (AS) market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818